According to the recent Contract Pharma Outsourcing Survey, 37% of respondents at virtual pharma companies expect to increase their outsourcing spending over the next year. Not surprisingly, but significantly, 75% of virtual pharma companies report that they outsource clinical manufacturing to CMOs while 88% reported outsourcing their API manufacturing to CMOs.
With virtual pharma companies relying on CMOs with mission critical work, the job of selecting a CMO is vital. Yet one of the challenges virtual pharmas face is that they need kilogram quantities made for toxicological studies — while their investors may be holding back funding until certain successful milestones are achieved.
Here are seven important criteria to help virtual pharmas as they select the best possible CMO partner: